Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anthem Joins Other Large Insurers In ‘Artificial Pancreas’ Coverage

Executive Summary

The largest US insurers have now all agreed to cover "artificial pancreas" system. Medtronic’s MiniMed 670G became the first fully closed-loop insulin pump/continuous glucose monitor system to win FDA approval in September 2016.

You may also be interested in...



Medtronic Enters New Outcomes-Based Insulin Pump Deal With Aetna

The device-maker will be on the hook to provide rebates to the health insurer if its self-adjusting insulin pumps don't maintain patients in appropriate glucose ranges, under a newly inked agreement. Medtronic already has a similar arrangement with UnitedHealthcare.

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

US FDA Approves First 'Artificial Pancreas' In Medtronic's MiniMed 670G

The hybrid closed-loop automated insulin delivery system, the first closed-loop system approved anywhere in the world, automatically monitors glucose and provides appropriate basal insulin doses in people with type 1 diabetes.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT121836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel